Sign up to save your podcasts
Or
Share Phase 3 Trials in Wet AMD [Miniseries: The Art of Drug Choice: Wet AMD and the Latest Data] (New Retina Radio)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Phase 3 Trials in Wet AMD [Miniseries: The Art of Drug Choice: Wet AMD and the Latest Data] (New Retina Radio)
In episode 2 of the NRR miniseries "The Art of Drug Choice: Wet AMD and the Latest Data," Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?
View all episodes
In episode 2 of the NRR miniseries "The Art of Drug Choice: Wet AMD and the Latest Data," Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?